



## Eleven Biotherapeutics to Present at Stifel 2017 Healthcare Conference

November 9, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, will present a company overview at the Stifel 2017 Healthcare Conference in New York on Wednesday, November 15, 2017 at 3:30 p.m. EST.

A live webcast can be accessed from the Investors & Media section of Eleven's website, [www.elevenbio.com](http://www.elevenbio.com). An archived replay of the webcast will be available on the Company's website for 90 days after the conference.

### About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a late-stage, clinical oncology company advancing novel product candidates based upon the Company's targeted protein therapeutics (TPTs) platform. The Company's TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistant mechanisms. Additionally, the Company believes that its TPT's cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more information, please refer to the Company's website at [www.elevenbio.com](http://www.elevenbio.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171109005480/en/>

Source: Eleven Biotherapeutics, Inc.

Stern Investor Relations, Inc.  
Michael Schaffzin, 212-362-1200  
[michael@sternir.com](mailto:michael@sternir.com)